Ocuphire Extends US Patent Protection for Drug Candidate Nyxol for Reversal of Mydriasis by 5 More Years Into 2039

Ocuphire Pharma announced the issuance of a new U.S. Patent (No. 11,400,077), which provides added intellectual property protection for the company’s late-stage product candidate, Nyxol (phentolamine mesylate), with claims directed to methods for treating mydriasis using phentolamine mesylate. The patent is eligible for listing in the FDA Orange Book and has a term extending into year 2039.

“We are very pleased with the issuance of this new patent for Nyxol, which extends our intellectual property protection in the U.S. by an additional 5 years into 2039,” Mina Sooch, MBA, Founder and CEO of Ocuphire Pharma, said in a company news release. “Last year, we were granted a new US Patent for presbyopia extending our existing patent estate into year 2039 and now we are very pleased with the issuance of this new patent for Nyxol in reversal of mydriasis. As we own the worldwide rights to Nyxol for all indications, this added protection will position us to maximize the commercial value of Nyxol for at least 15 years in reversal of mydriasis as we plan to submit an NDA to the FDA later this year. If approved, Nyxol could be launched in the second half of 2023.”